ArticleJournal of molecular histology2025
MAO-A inhibition alleviates sepsis-driven lung injury via Nrf2/HO-1 pathway activation and suppression of pyroptosis.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extensive research has highlighted the involvement of excessive oxidative stress and pyroptosis in sepsis-caused acute lung injury (ALI). The present investigation delves into the potential role of Monoamine oxidase A (MAO-A) in this pathological process. Analyzing Gene Expression Omnibus (GEO) datasets alongside clinical samples revealed a significant upregulation of MAO-A in sepsis patients. To further elucidate this, cecal ligation puncture (CLP)-induced ALI were established in C57BL/6 mice. Additionally, human alveolar epithelial cells (HPAEpiC) treated with MAO-A inhibitor RO11-11639 were subjected to lipopolysaccharide (LPS) stimulation in vitro. The in-vivo experiments demonstrated that RO11-11639 mitigated CLP-induced ALI, significantly reducing pulmonary oxidative stress, inflammation and pyroptosis in lung tissue. Biochemical quantification revealed significant suppression of both oxidative stress biomarkers reactive oxygen species (ROS), malondialdehyde (MDA) and key inflammatory markers interleukin (IL)-1β, IL-16. Consistent with these findings, the in-vitro model confirmed that RO11-11639 reduced ROS and MDA accumulation, and inflammation in HPAEpiC, in response to LPS stimulation. Moreover, functional rescue analysis delineated the nuclear factor erythropoietin-2-related factor 2/heme oxygenase 1 (Nrf2/HO-1) pathway as the critical mediator of RO11-11639's dual antioxidant and anti-pyroptosis activities in HPAEpiC. Mechanistically, MAO-A inhibition promoted the nuclear translocation of Nrf2, thereby activating the downstream regulatory proteins HO-1, quinone oxidoreductase 1 (NQO-1) and glutathione s-transferase (CST). These data cumulatively indicate that pharmacological targeting of MAO-A may offer therapeutic benefits in septic ALI by attenuating pathophysiological processes involving oxidative damage and inflammasome-mediated pyroptosis.
Indexed as
Identifiers
40944790What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.